Trial Profile
Prospective study of predictive markers in nivolumab immunotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer
- Focus Pharmacodynamics
- 27 Sep 2016 New trial record